Telemedicine gets pitched with a simple headline: “It’s cheaper than urgent care.” And sometimes it is, on a per-visit basis. A typical cash-pay telehealth visit runs roughly $40 to $90, against $150 to $280 for urgent care, so the per-visit gap is real.
But if you’re responsible for a health plan budget, you know the uncomfortable truth: employers don’t renew on “cost per visit.” They renew on claims experience, pharmacy trend, and how much spend shows up in the system over the year.
Per-visit pricing against urgent care is the wrong comparison. The comparison that matters is telemedicine that prevents claims vs. telemedicine that simply creates different claims.
Does telemedicine become a claim?
This is the fork in the road that changes everything. Two employers can both “offer telehealth” and end up with completely different financial outcomes depending on where the dollars flow.
Model A: Telemedicine as a medical claim
In the most common setup, telemedicine visits are processed through the carrier or TPA like any other service. The visit is still a medical claim, with an allowed amount, an EOB, and a place in your experience data.
- It increases claim count (even if the unit cost is lower than other settings).
- It can influence renewals for fully insured plans and reporting for self-funded plans.
- It can introduce member friction if cost-sharing applies (copays/deductibles).
In this model, “telemedicine savings” often depend on a vendor’s assumptions about what the member would have done otherwise. If those assumptions are optimistic, the ROI won’t show up where you need it: at renewal.
Model B: Telemedicine designed to avoid claims
A different architecture treats telemedicine as a $0-friction, used-first benefit that solves problems before they hit the medical claims channel. The goal isn’t just a cheaper visit. It’s claims avoidance, and being able to prove it.
When evaluating programs, ask yourself what you’re really buying: convenience, or a mechanism that actually changes the claim trajectory.
The tele-visit isn’t the cost event: the next 90 days are
Most cost comparisons get sloppy here. A telemedicine encounter is often just the start of a chain reaction. The same “$40 visit” can lead to very different downstream outcomes.
- Advice only (best-case financially): the issue is resolved without additional services.
- Prescription issued: cost shifts to the pharmacy channel, where PBM pricing and plan design matter a lot.
- Labs or imaging ordered: total spend depends heavily on site-of-care and pricing steerage.
- In-person referral: sometimes appropriate and cost-saving long term, sometimes just more utilization.
For an honest comparison, don’t stop at “cost per tele-visit.” Track downstream allowed amounts tied to tele-visits over 30/90 days, separately for medical and Rx.
Steerage is the difference between “telehealth” and savings
Telemedicine doesn’t save money because it’s virtual. It saves money when the program can route people to lower-cost, higher-value paths and help them complete the right next step.
When comparing vendors, look for real steerage levers, not vague promises.
- Site-of-care steering: keeping avoidable cases out of the ER and directing to appropriate settings.
- Lab steering: avoiding high-priced hospital outpatient billing when a lower-cost option is appropriate.
- Pharmacy steering: reducing spread-pricing exposure and improving price transparency where possible.
- Follow-up closure: confirming the member completed the next step instead of dropping off.
- Waste controls: preventing low-value, high-frequency utilization that looks like “engagement” but drives spend.
A practical, CFO-ready way to compare telemedicine options
If you’re making a real decision, not just picking the shiniest demo, use a framework that reflects how plan costs actually behave.
1) Segment the use cases
Telemedicine is not one bucket. At a minimum, evaluate these separately because they produce different financial and workforce outcomes.
- Acute minor illness/injury
- Behavioral health
- Chronic condition support
- Preventive action facilitation (screenings, adherence, monitoring)
For example, behavioral health can increase near-term spend while improving retention and productivity. Treating it like an urgent care replacement is a category error.
2) Measure claim displacement (not just “substitution” surveys)
Many vendors rely on member surveys to claim that telemedicine replaced urgent care or the ER. Surveys are useful, but they’re not financial proof. A 2017 RAND study published in Health Affairs found that while vendor surveys suggested only about 10 percent of visits were net-new, commercial claims data on more than 300,000 patients showed 88 percent represented new utilization. Net annual spending on acute respiratory illness rose $45 per telehealth user as a result.
Push for data that ties tele-visits to actual downstream utilization patterns and costs.
3) Calculate a 90-day net impact
Net impact = program fees + tele-visit costs + downstream medical allowed amounts + downstream Rx allowed amounts − avoided high-cost claims (based on site-of-care deltas)
This is the comparison that separates a low-cost access point from a program that truly changes spend.
4) Don’t ignore admin and compliance costs
Some of the biggest telemedicine “costs” don’t show up on a proposal. They show up as HR tickets, employee confusion, and compliance work.
- HIPAA: vendor risk reviews, BAAs, security posture
- ERISA: whether plan documents/SPDs need updating based on how the benefit is structured
- Eligibility operations: file feeds, timing, term handling, and who owns errors
- Employee experience: billing disputes and confusion create real operational drag
Why savings often don’t show up at renewal
Even when telemedicine is working, it may not immediately move renewal numbers. Renewals are heavily influenced by large claimants and pharmacy trend. Telemedicine often improves small-claim patterns while a couple of shock claims dominate the year.
That’s why telemedicine works best when it’s part of a larger strategy that can prove behavior change and then unlock bigger levers (pharmacy economics, smarter routing, and structural plan improvements).
Behavioral health telemedicine depends on prescribing rules that expire December 31, 2026
Behavioral health is the telemedicine use case with the most continuity risk. Part of it runs on temporary rules. Under the COVID-era flexibilities, DEA-registered practitioners can prescribe Schedule II-V controlled medications via audio-video telemedicine without a prior in-person visit. DEA and HHS have extended those flexibilities through December 31, 2026, and in 2024 more than 7 million controlled-substance prescriptions were issued via telemedicine without a prior in-person visit. The people who rely on this pathway include those receiving treatment for mental health conditions and substance use disorder.
For an employer, the implication is straightforward: a telemedicine vendor’s behavioral health offering is only as stable as its prescribing pathway. When Medicare telehealth flexibilities lapsed in September 2025, fee-for-service telemedicine visits fell 24 percent. Before you buy, ask any behavioral health vendor what happens to member prescriptions if the flexibilities are not extended again, and whether the program can transition members to in-person care without a gap.
The five questions to ask before you buy
Ask these five questions in every telemedicine evaluation. They’ll get you past marketing and into real economics.
- Does a tele-visit generate a medical claim? If yes, where does it land and how does it affect experience?
- What’s the 30/90-day downstream allowed amount per tele-visit (medical + Rx), broken out by visit category?
- How much utilization is net-new versus truly displaced from higher-cost settings?
- What steerage exists for labs, referrals, and prescriptions, and how is completion verified?
- What’s the operational and compliance footprint (HIPAA/BAA, ERISA docs, eligibility, employee support burden)?
Bottom line
A telemedicine cost comparison that focuses only on “telehealth vs urgent care” is too small for the decision you’re making.
The better comparison is this: Does the program reduce claims and downstream spend in a provable way, or does it simply make access easier while costs quietly migrate elsewhere?
When you evaluate telemedicine like a benefits system, checking claims routing, steerage, verification, and operational reality, you get a decision that holds up with HR, finance, and leadership alike.